SIREN : 891001430
DR HOUSE is a French company founded 5 years ago, specialized in the sector Travaux d'isolation. Based in DOMPIERRE-SUR-MER (17139), this company of category PME shows in 2024 a revenue of 994 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 993 877 € | 1 105 884 € | 616 759 € |
| Net income | 106 531 € | 3 878 € | -526 € |
| EBITDA | 146 864 € | 30 104 € | -46 € |
| Net margin | 10.7% | 0.4% | -0.1% |
In 2024, DR HOUSE achieves revenue of 994 k€. Over the period 2022-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +26.9%. Significant drop of -10% vs 2023. After deducting consumption (173 €), gross margin stands at 994 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 147 k€, representing 14.8% of revenue. Positive scissor effect: EBITDA margin improves by +12.1 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 107 k€, i.e. 10.7% of revenue. This profit can be retained or distributed to shareholders.
993 877 €
993 704 €
146 864 €
146 054 €
106 531 €
14.6%
The debt ratio (= Financial debt / Equity x 100) stands at 110%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 10%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 10.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
110.232%
10.366%
10.692%
1.168
56.1%
In 2024, the debt ratio of DR HOUSE (110.23) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of DR HOUSE (10.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of DR HOUSE (1.17) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 127.64. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 5.6x. Operating income very largely covers interest expenses: high safety margin.
127.638
5.647
In 2024, the liquidity ratio of DR HOUSE (127.64) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of DR HOUSE (5.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 283 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 247 days. The gap of 36 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 122 days of revenue, i.e. 337 k€ to permanently finance. Over 2022-2024, WCR increased by +73%, requiring additional financing.
337 063 €
283 j
247 j
0 j
122 j
Based on 58 transactions of similar company sales
(all years),
the value of DR HOUSE is estimated at
229 521 €
(range 151 863€ - 525 865€).
With an EBITDA of 146 864€, the sector multiple of 1.2x is applied.
The price/revenue ratio is 0.20x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 58 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DR HOUSE with other companies in the same sector:
The revenue of DR HOUSE in 2024 is 994 k€.
Yes, DR HOUSE generated a net profit of 107 k€ in 2024.
The headquarters of DR HOUSE is located in DOMPIERRE-SUR-MER (17139), in the department Charente-Maritime.
The tax return of DR HOUSE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DR HOUSE operates in the sector Travaux d'isolation (NAF code 43.29A). See the 'Sector positioning' section above to compare the company with its competitors.